Attached files

file filename
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-2.htm
EX-10.54 - FORM OF AMENDMENT AGREEMENT - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-54.htm
10-K - FORM 10-K - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10k_dec312015.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in the registration statements on Form S-8 (Nos. 333-44826, 333-58020, 333-118614, 333-135396, 333-161132,333-174355 and 333-203200) and Form S-3 (No. 333-176121), of MabVax Therapeutics Holdings, Inc., of our report dated March 14, 2016, related to our audit of the consolidated financial statements of MabVax Therapeutics Holdings, Inc., as of December 31, 2015 and 2014 and for the years then ended, which report included an explanatory paragraph relating to MabVax Therapeutics, Inc.’s ability to continue as a going concern, included in this Annual Report on Form 10-K.
 
/s/ CohnReznick LLP
 
San Diego, California
March 14, 2016